This work aimed to study the relationship of the acetylator phenotype with the features of the clinical course of brucellosis in patients to develop prognostic criteria for the development of complications and indications for the use of antibiotics depending on the degree of N acetyltransferase activity. Materials and methods. The study included 178 patients with various clinical forms of brucellosis. The acetylation phenotype was determined in urine by the method of A.M. Timofeeva modified by G.A. Ponomarev. Results. The results obtained showed that brucellosis in SA has a longer duration with destructive and necrotic lesions of organs such as the myocardium, liver, brain, and joints. Since the process of SA is sluggish, intermediate products of inflammation accumulate in the body, and high endogenous intoxication develops. The transition of an acute process to a chronic one increases. The conducted antibiotic therapy has a positive effect since a high concentration of the antibiotic accumulates in the body, but the toxic effect of the drug on the liver increases. For patients with FA the process proceeds quickly, due to this, endogenous intoxication in patients is low, the antibiotic therapy carried out is temporary, since the antibiotic is released from the body faster and the expected effect is not observed. Due to this, in 24.5% of adults with FA, the acute process becomes chronic. Conclusions: obligatory determination of the type of acetylation phenotype: in cases of detection of a slow type of acetylation, the appointment of combined antibiotic therapy should be controlled depending on the value of ABL to the TA of the joints with cancellation or continuation of treatment and add hepatoprotection to prevent hepatotoxic effect and detoxification therapy; in cases of detection of a rapid type of acetylation, the appointment of a longer course of combined antibiotic therapy, depending on the value of ABL to TA of the joints, cancel or continue treatment.

N acetyltransferase, Acetylation phenotype, Patient stratification, Individualization of treatment

[1]Bruce D. Note on the discovery of a microorganism in Malta Fever. Practitioner 1887; 36: 161–70.

[2]Wyatt HV. Sir Themistocles Zammit: His honors and an annotated bibliography of his medical work. Maltese Med J 2000; 12:27–30.

[3]Araj GF. Human brucellosis revisited: a persistent saga in the Middle East. BMJ (Middle East) 2000; 7: 6–15.

[4]Pappas G, Papadimitriou P, Akritidis LN, Christou, Tsianos E. The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91–9.

[5]Lulu AR, Araj GF, Khateeb MI, Mustafa MY, Yusuf AR, Fenech FF. Human brucellosis in Kuwait: a prospective study of 400 cases. Quart J Med 1988; 66: 39–54.

[6]Young EJ. An overview of human brucellosis. Clin Infect Dis 1995; 21: 283–90.

[7]Memish ZA, Balkhy HH. Brucellosis and international travel. J Travel Med 2004; 11: 49–55.

[8]Godfroid J, Cloeckaert A, Liautard J, Kohler S, Fretin D, Walravens K, et al. From the discovery of the Malta fever’s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res 2005; 36: 313–26.

[9]Greenfield RA, Drevets DA, Machado LJ, Voskuhl GW, Cornea P, Bronze MS. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J. Med Sci 2002; 323: 299–315.

[10]Pappas G, Pangopoulou P, Christou L, Akritidis N. Category B potential bioterrorism agents: bacteria, viruses, toxins, and foodborne and waterborne pathogens.Infect Dis Clin North Am 2006; 20: 395–421.

[11]Kukes, V.G. Clinical pharmacology and pharmacotherapy /

V.G. Kukes [and others]; under total. ed. by V.G. Kukes, A.K. Starodubtseva. - 2nd ed., Rev. - M.: GEOTAR - Media, 2006.

- P. 640.

Baranov, V. Detoxification genes responsible for the biotransformation of xenobiotics / V. Baranov // Molecular biology. - 2000. - T.34, No. 4. - P. 686 Marsh, S. Global pharmacogenetics: giving the genome to the masses /

S. Marsh, D. J. van Booven, H. L. McLeod // Pharmacogenomics. - 2006. - Vol.7, № 4. - 625-631.

[12]Polymorphism discovery in 51 chemotherapy pathway genes

/ R. R. Freimuth [et. al.] // Hum. Mol. Genet. - 2005. - Vol. 14,

№ 23. - 3595-3603.

[13]Sychev, D.A. Pharmacogenetic testing: Clinical interpretation of the results. Recommendations for practicing doctors / D.A. Sychev; under total. ed. D.A. Sychev. - Moscow, 2011.- 10-12, Р. 72-76.

[14]Mirrakhimova, N.M. Some immuno-cytochemical indicators of acute brucellosis: materials of the Republican scientific and practical conference with international participation "Infections and drug resistance" / N.M. Mirrakhimova, Kh. Yu. Akhmedova, Sh. R. Azimov // Infection, immunity and pharmacology. - Tashkent, 2017. -- spec. release. Part 1. - P. 135-140 - Bibliography: 7 titles.

[15]Kasymov I.A. Immunological characteristics of chronic forms of brucellosis: scientific publication / I.A. Kasymov // Journal of theoretical and clinical medicine. - Tashkent, 2014.

- Volume 2 №3. - P. 54.

[16]Garmonov S.Yu., Nugbienho L.K., Salakhov I.A., Kiseleva

T.A. Bukharov S.V. Chromatographic determination of procainamide in urine as a test for assessing the phenotype of acetylation of the human body // Medical Almanac. -. 2017- No.2 (47) S. 135-137.

[17]Gorbacheva E.V., Suleimanov S. Sh., Uchaikin GF Features of the acetylation phenotype and the value of calcium pantothenate in children with shigellosis. // Materials of the scientific-practical conference of pediatricians of Russia "Pharmacotherapy and pharmacogenetics in pediatrics." Moscow, 2000. - P. 42.

[18]Garib F. Yu., Gurarii NI, Garib VF Method for determining subpopulations of lymphocytes // Rasmiy akhborotnoma. - Tashkent, 1995. - No. 1. - P. 90.

[19]Sycheva D.A. Clinical pharmacogenetics: textbook. allowance / under total. ed. by V.G. Kukes, N.P. Bochkova. - Moscow: "GEOTAR - Media", 2007. - S. 248-267.

[20]Graham-Smith, D.G. Oxford Handbook of Clinical Pharmacology and Pharmacotherapy: translation from English / D.G. Graham-Smith, J.K. Aronson. - Moscow: Medicine, 2000 - S. 108-109.

[21]Zgheib NK, Shamseddine AA, Geryess E, Tfayli A, Bazarbachi A, Salem Z, et al. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated withrisk of breast cancer in a sample of Lebanese women. MutatRes 2013; - S. 747-748.

[22]Tiago Donizetti da Silva, Aledson Vitor Felipe, Jacqueline Miranda de Lima, Nora Manoukian Forones N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer. World journal of gastroenterology 2011 First Publication: 14 February 2011.